| Feature |
Hodgkin Lymphoma |
Non-Hodgkin Lymphoma |
| Cell of Origin |
B lymphocytes, specifically characterized by the presence of Reed-Sternberg cells, which are large, abnormal B cells.
|
Can originate from either B lymphocytes (B-cell lymphomas) or T lymphocytes (T-cell lymphomas). Reed-Sternberg cells are absent.
|
| Age Group |
Bimodal age distribution, most commonly affects young adults (ages 15-35) and older adults (over 55 years).
|
Can occur at any age, but incidence increases with age, especially common in older adults.
|
| Symptoms |
- Painless lymph node swelling, often in the neck, armpits, or groin.
- Fever, night sweats, and weight loss (B symptoms).
- Fatigue and generalized itching (pruritus).
|
- Painless lymph node enlargement, may be widespread.
- Fever, night sweats, weight loss (B symptoms) are less common but can occur.
- Fatigue, abdominal pain or swelling, chest pain, or cough depending on the lymph nodes affected.
|
| Spread Pattern |
Typically spreads in a predictable, contiguous manner from one group of lymph nodes to another.
|
Can spread in a non-contiguous, unpredictable pattern, often involving extranodal sites such as the gastrointestinal tract, skin, or bone marrow.
|
| Subtypes |
Primarily Classical Hodgkin Lymphoma (CHL) with subtypes: Nodular Sclerosis, Mixed Cellularity, Lymphocyte-Rich, Lymphocyte-Depleted.
|
Many subtypes classified as B-cell or T-cell lymphomas. Common B-cell subtypes include Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, and Burkitt Lymphoma.
|
| Prognosis |
Generally good with a high cure rate, especially when diagnosed early. The 5-year survival rate is high.
|
Varies widely depending on the subtype, stage at diagnosis, and patient factors. Indolent lymphomas may have a chronic course, while aggressive lymphomas can be curable with intensive treatment.
|
| Treatment |
- Chemotherapy (ABVD regimen is common).
- Radiation therapy, especially in early stages.
- Stem cell transplantation in relapsed or refractory cases.
|
- Chemotherapy (varies by subtype, e.g., CHOP regimen for DLBCL).
- Immunotherapy (e.g., rituximab for B-cell lymphomas).
- Targeted therapy, radiation therapy, stem cell transplantation in selected cases.
|